High activity 90Y-ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas
Pier F. Ferrucci, Anna Vanazzi, Chiara M. Grana, Marta Cremonesi, Mirco Bartolomei, Marco Chinol, Mahila Ferrari, Davide Radice, Stefano Papi, Giovanni Martinelli, Giovanni PaganelliVolume:
139
Année:
2007
Langue:
english
Pages:
10
DOI:
10.1111/j.1365-2141.2007.06869.x
Fichier:
PDF, 242 KB
english, 2007